GPI不活性化によるペントースリン酸経路フラックスのスイッチオンを介したグリア腫幹細胞におけるテモゾロミド耐性の誘導

Temozolomide (TMZ) resistance in glioblastoma (GBM) remains a substantial clinical challenge. Targeting glioma stem cells (GSCs) represents a promising strategy to overcome chemoresistance and tumor recurrence. In this study, we found that GSCs maintain chemoresistance by increasing pentose phosphate pathway (PPP) flux compared with differentiated tumor cells. Following TMZ treatment, the activity of glucose-6-phosphate isomerase (GPI), a key glycolytic enzyme that catalyzes the conversion of glucose-6-phosphate to fructose-6-phosphate, was significantly suppressed in GSCs. Mechanistically, Ataxia Telangiectasia Mutated (ATM), activated by TMZ-induced DNA damage, phosphorylates polo-like kinase 1 (PLK1), promoting its nuclear export. PLK1 subsequently phosphorylates GPI at T215, leading to suppression of GPI activity. Targeting the ATM/PLK1/GPI axis through combinational treatment with rigosertib may therefore represent a therapeutic strategy. Moreover, PLK1 expression and GPI pT215 levels may serve as potential candidate markers for GBM. Collectively, activation of the ATM/PLK1/GPI axis plays a critical role in regulating PPP flux and TMZ resistance in GSCs.